NCT00550355 - Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

PD 0360324

3 doses of PD 0360324 (Dose level 1) administered over 12 weeks

DRUG

PD 0360324

3 doses of PD 0360324 (Dose level 2) administered over 12 weeks

DRUG

PD 0360324

3 doses of PD 0360324 (Dose level 3) administered over 12 weeks

DRUG

Placebo

3 doses of Placebo administered over 12 weeks

Trial Locations (25)

1606

Pfizer Investigational Site, Sofia

1612

Pfizer Investigational Site, Sofia

5800

Pfizer Investigational Site, Pleven

14050

Pfizer Investigational Site, Mexico City

15705

Pfizer Investigational Site, Santiago de Compostela

16635

Pfizer Investigational Site, Duncansville

21702

Pfizer Investigational Site, Frederick

32114

Pfizer Investigational Site, Daytona Beach

32127

Pfizer Investigational Site, Port Orange

66211

Pfizer Investigational Site, Overland Park

66212

Pfizer Investigational Site, Overland Park

75231

Pfizer Investigational Site, Dallas

85381

Pfizer Investigational Site, Peoria

48910-8595

Pfizer Investigational Site, Lansing

C1013AAR

Pfizer Investigational Site, Buenos Aires

656 91

Pfizer Investigational Site, Brno

140 59

Pfizer Investigational Site, Prague

06700

Pfizer Investigational Site, México

15-461

Pfizer Investigational Site, Bialystok

15-875

Pfizer Investigational Site, Bialystok

31-201

Pfizer Investigational Site, Krakow

31-752

Pfizer Investigational Site, Krakow

02-637

Pfizer Investigational Site, Warsaw

51-124

Pfizer Investigational Site, Wroclaw

921 01

Pfizer Investigational Site, Piešťany